These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 20624009

  • 1. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?
    Gremmel T, Calatzis A, Steiner S, Kaider A, Seidinger D, Koppensteiner R, Kopp CW, Panzer S.
    Platelets; 2010; 21(7):515-21. PubMed ID: 20624009
    [Abstract] [Full Text] [Related]

  • 2. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [Abstract] [Full Text] [Related]

  • 3. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D, Magyarlaki T, Tokés-Füzesi M, Rideg O, Vorobcsuk A, Komócsi A.
    Platelets; 2010 Oct; 21(7):563-70. PubMed ID: 20642320
    [Abstract] [Full Text] [Related]

  • 4. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
    von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schömig A, Kastrati A.
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [Abstract] [Full Text] [Related]

  • 6. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [Abstract] [Full Text] [Related]

  • 7. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A, Cerletti C, de Gaetano G.
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [Abstract] [Full Text] [Related]

  • 8. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Transl Res; 2013 May; 161(5):421-9. PubMed ID: 23340049
    [Abstract] [Full Text] [Related]

  • 9. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T, Panzer S, Steiner S, Seidinger D, Koppensteiner R, Pabinger I, Kopp CW, Ay C.
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L.
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [Abstract] [Full Text] [Related]

  • 12. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, Willheim M, Hübl W, Wojta J, Huber K.
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [Abstract] [Full Text] [Related]

  • 13. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
    Kim IS, Jeong YH, Tantry US, Park Y, Lee DH, Bliden KP, Koh JS, Park JR, Jang JS, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S, Gurbel PA.
    Am Heart J; 2013 Jul; 166(1):95-103. PubMed ID: 23816027
    [Abstract] [Full Text] [Related]

  • 14. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
    Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, Kastrati A, von Beckerath N.
    Thromb Haemost; 2008 Jan; 99(1):121-6. PubMed ID: 18217143
    [Abstract] [Full Text] [Related]

  • 15. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
    Cuisset T, Hamilos M, Delrue M, Frère C, Verhamme K, Bartunek J, Saut N, Bonnet JL, Eijgelsheim M, Wijns W, Alessi MC, Barbato E.
    Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
    [Abstract] [Full Text] [Related]

  • 16. Variability in aggregometry response before and after initiation of clopidogrel therapy.
    Meen Ø, Brosstad F, Bjørnsen S, Pedersen TM, Erikssen G.
    Scand J Clin Lab Invest; 2009 Apr; 69(6):673-9. PubMed ID: 19484660
    [Abstract] [Full Text] [Related]

  • 17. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.
    Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG.
    Thromb Res; 2009 Sep; 124(4):418-22. PubMed ID: 19250657
    [Abstract] [Full Text] [Related]

  • 19. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
    Gurbel PA, Bliden KP, Etherington A, Tantry US.
    Thromb Res; 2007 Sep; 121(1):107-15. PubMed ID: 17400283
    [Abstract] [Full Text] [Related]

  • 20. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    Gremmel T, Kopp CW, Seidinger D, Koppensteiner R, Steiner S, Panzer S.
    Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.